In vivo investigations on the cholinesterase-inhibiting effects of tricyclic quinazolinimines: Scopolamine-induced cognitive impairments in rats are attenuated at low dosage and reinforced at higher dosage

Pflugers Archiv European Journal of Physiology

Volumn 455, Issue 5, 2008, Pages 895-901

  Appenroth, D ^a   Decker, M ^a   Trankle C ^b   Mohr, K ^b   Lehmann, J ^a   Fleck, C ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Acetylcholine; Acetylcholinesterase; ACh; Allosteric modulation; Memory; Quinazolinimines; Radial maze; Rat; Scopolamine

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MD 212; MUSCARINIC RECEPTOR; N BENZYL N (6,7,8,9,10,11 HEXAHYDRO 13H AZOCINO[2,1 B]QUINAZOLIN 13 YLIDENE)AMINE; QUINAZOLINE DERIVATIVE; SCOPOLAMINE; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BRAIN PROTECTION; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; FEMALE; IN VIVO STUDY; LOW DRUG DOSE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ALLOSTERIC REGULATION; ANIMALS; AZOCINES; CHOLINERGIC ANTAGONISTS; CHOLINESTERASE INHIBITORS; COGNITION; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; IMINES; MAZE LEARNING; MEMORY, SHORT-TERM; QUINAZOLINES; RATS; RATS, WISTAR; SCOPOLAMINE; TRITIUM;

EID: 37249061212     PISSN: 00316768     EISSN: 14322013     Source Type: Journal    
DOI: 10.1007/s00424-007-0325-0     Document Type: Article

References (40)

1. Bassant MH, Jazat-Poindessous F, Lamour Y (1996) Effects of metrifonate, a cholinesterase inhibitor, on local cerebral glucose utilization in young and aged rats. J Cereb Blood Flow Metab 16:1014-1025
2. Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, Perl DP, Schmeidler J, Kanof P, Davis KL (1995) Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 64:749-760
3. Christopoulos A, Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374
4. Decker M (2005) Novel inhibitors of acetyl- and butyrylcholinesterase derived from the alkaloids dehydroevodiamine and rutaecarpine. Eur J Med Chem 40:305-313
5. Decker M (2006) Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterases with dirigible selectivity toward butyrylcholinesterase. J Med Chem 49:5411-5413
6. Decker M, Krauth F, Lehmann J (2006) Novel tricyclic quinazolinimines and related tetracyclic nitrogen bridgehead compounds as cholinesterase inhibitors with selectivity towards butyrylcholinesterase. Bioorg Med Chem 14:1966-1977
7. Eckerman DA, Gordon WA, Edwards JD, McPhail R, Gage MI (1980) Effects of scopolamine, pentobarbital, and amphetamine on radial arm maze performance in the rat. Pharmacol Biochem Behav 12:595-602
8. Ellis JM (2005) Cholinesterase inhibitors in the treatment of dementia. J Am Osteopath Assoc 105:145-158
9. Ellis J, Huyler J, Brann MR (1991) Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes. Biochem Pharmacol 42:1927-1932
10. Fisher A, Hanin I (1986) Potential animal models for senile dementia of Alzheimer's type, with emphasis on AF64A-induced cholinotoxicity. Ann Rev Pharmacol Toxicol 26:161-181
11. Fisher A, Bar-Ner RHN, Kligal-Spatz M, Naton N, Sonego H, Marcovitch I, Pittel Z (2002) AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. J Mol Neurosci 19:145-153
12. Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66:137-147
13. Giacobini E (2004) Drugs that target cholinesterases. In: Buccafusco JJ (ed) Cognitive enhancing drugs. Birkhäuser, Basle-Boston-Berlin, pp 11-36
14. 2 acetylcholine receptors: evidence for a major conformational change upon binding of an orthosteric agonist instead of an antagonist. Naunyn Schmiedebergs Arch Pharmacol 372:267-276
15. Holzgrabe U, De Amici M, Mohr K (2006) Allosteric modulators and selective agonists of muscarinic receptors. J Mol Neurosci 30:165-168
16. Holzgrabe U, Kapkova P, Alptuezuen V, Scheiber J, Kugelmann E (2007) Targeting acetylcholinesterase to treat neurodegeneration. Expert Opin Ther Targets 11:161-179
17. Jepsen K, Lüllmann H, Mohr K, Pfeffer J (1988) Allosteric stabilization of 3H-N-methylscopolamine binding in guinea-pig myocardium by an antidote against organophosphate intoxication. Pharmacol Toxicol 63:163-168
18. Johnson G, Moore SW (2006) The peripheral anionic site of acetylcholinesterase: Structure, functions and potential role in rational drug design. Curr Pharm Des 12:217-225
19. Kords H, Lüllmann H, Ohnesorge FK, Wassermann O (1968) Reduction in the toxicity of diisopropylfluorophosphate (DFP) by atropine and derivatives of hexane-bis-ammonium. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 260:157-158
20. Kostenis E, Mohr K (1996) Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation. Trends Pharmacol Sci 17:280-283
21. Lane RM, Potkin SG, Enz A (2006) Targeting acetylcholinesterase and butyrylcholinestrase in dementia. Int J Neuropharmacol 9:101-124
22. Messer JS Jr (2004) Drugs that target muscarinic cholinergic receptors. In: Buccafusco JJ (ed) Cognitive enhancing drugs. Birkhäuser, Basle-Boston-Berlin, pp 37-49
23. Ni JW, Ohta H, Matsumoto K, Watanabe H (1994) Progressive cognitive impairment following chronic cerebral hypoperfusion induced by permanent occlusion of bilateral carotid arteries in rats. Brain Res 653:231-236
24. Ni JW, Matsumoto K, Li HB, Murakami Y, Watanabe H (1995) Neuronal damage and decrease of central acetylcholine level following permanent occlusion of bilateral common carotid arteries in rat. Brain Res 673:290-296
25. Nordberg A (2006) Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer's disease. Alzheimer Dis Assoc Disord 20:S12-S18
26. Park CH, Lee Y-J, Lee SH, Choi SH, Kim H-S, Jeong S-J, Kim SS, Suh YH (2000) Dehydroevodiamine HCl prevents impairment of learning and memory and neuronal loss in rat models of cognitive disturbance. J Neurochem 74:244-253
27. Potter LT, Ferrendelli CA, Hanchett HE, Hollifield MA, Lorenzi MV (1989) Tetrahydroaminoacridine and other allosteric antagonists of hippocampal M1 muscarine receptors. Mol Pharmacol 35:652-660
28. Rawlins JNP, Deacon RMJ (1993) Further developments of maze procedures. In: Sahgal A (ed) Behavioural neuroscience, Vol. I: A practical approach. IRL, Oxford, pp 95-122
29. Rubio A, Perez M, Avila J (2006) Acetylcholine receptors and tau phosphorylation. Cur Molec Med 6:423-428
30. Rush DK (1988) Scopolamine amnesia of passive avoidance: a deficit of information acquisition. Behav Neural Biol 50:255-274
31. Tanaka K, Mizukawa K, Ogawa N, Mori A (1995) Post-ischemic administration of the acetylcholinesterase inhibitor ENA-713 prevents delayed neuronal death in the gerbil hippocampus. Neurochem Res 20:663-667
32. 1-preferring agonist, talsaclidine. Psychopharmacol 162:292-300
33. 5 chimeric receptors. Mol Pharmacol 68:1597-1610
34. Tulyaganov N, Sadritdinov FS, Suleimanova GA (1986) The pharmacological characteristics of desoxypeganine hydrochloride. Farmakol Toksikol 49:37-40
35. Wang T, Tang XC (1998) Reversal of scopolamine-induced deficits in radial-arm maze performance by (-)huperizine A: comparison with E2020 and tacrine. Eur J Pharmacol 349:137-142
36. Wanibuchi F, Nishida T, Yamashita H, Hidaka K, Koshiya K, Tsukamoto S, Usuda S (1994) Characterization of a novel muscarinic receptor agonist, YM796; comparison with cholinesterase inhibitors in in vivo pharmacological studies. Eur J Pharmacol 265:151-158
37. Wess J (2005) Allosteric binding sites on muscarinic acetylcholine receptors. Mol Pharmacol 68:1506-1509
38. Wirsching BA, Beninger RJ, Jhamandas K, Boegman RJ, El Defrawy SR (1984) Differential effects of scopolamine on working and reference memory of rats in the radial maze. Pharmacol Biochem Behav 20:659-662
39. Yamaguchi Y, Higashi M, Matsuno T, Kawashima S (2001) Ameliorative effects of azaindolizinone derivative ZSET845 on scopolamine-induced deficits in passive avoidance and radial-arm maze learning in the rat. Jpn J Pharmacol 87:240-244
40. Yonemori F, Yamada H, Yamaguchi T, Uemura A, Tamura A (1996) Spatial memory disturbance after focal cerebral ischemia in rats. J Cereb Blood Flow Metab 16:973-980